Canagliflozin for heart health in patients with advanced kidney disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II clinical trial evaluates the effects of canagliflozin, a medication typically used for diabetes, on cardiac structure and function in patients with advanced chronic kidney disease (CKD) and those on dialysis. Participants will be randomly assigned to receive either canagliflozin or a placebo for one year, with the primary goal of assessing improvements in left ventricular hypertrophy through cardiac MRI. The study also aims to monitor other cardiac parameters and surrogate markers of efficacy, while ensuring that all other medications are managed by the treating physician.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* advanced CKD, defined as an estimated glomerular filtration rate (eGFR) \< 20 ml/min/1.73m2 not yet on dialysis OR incident hemodialysis or peritoneal dialysis patients (i.e., who were started on dialysis in the last 6 months)\*

  \* For patients who were not previously followed in a CKD clinic and for whom it is not clear whether dialysis was initiated after an acute deterioration in renal function that is potentially reversible, at least 90 days of dialysis will be required prior to enrolment. This criterion only applies to patients for whom baseline eGFR prior to the acute event was ≥ 20 ml/min/1.73m2 or was unknown. The average creatinine values over the last 12 months will be used to calculate baseline eGFR.
* LV hypertrophy, defined as LV mass \> 130 g/m2 in men and 100 g/m2 in females OR hospitalization for heart failure or atherosclerotic cardiovascular (CV) disease in the last 12 months OR type 2 diabetes OR UACR \> 200 mg/g on a morning spot urine collection (this criterion is not applicable to patients who are on dialysis and have a urine output \< 500 ml per day).

Exclusion Criteria:

* type 1 diabetes,
* history of euglycemic ketoacidosis,
* known hypersensitivity to sodium-glucose cotransporter-2 (SGLT-2) inhibitors,
* hemodynamic instability (defined as current use of parenteral inotropic agents),
* systolic BP \< 90 mmHg,
* severe liver cirrhosis (Child-Pugh class C stage),
* acute hepatitis (defined as an alanine aminotransferase \> 2.0 times the upper limit of normal \[ULN\] or total bilirubin \>1.5 times the ULN),
* recurrent severe genital or urine infections,
* patients receiving digoxin, phenobarbital, phenytoin, rifampin, or ritonavir if these agents cannot be safely discontinued (due to inhibition of the P-glycoprotein mediated efflux of digoxin by canagliflozin or induction of Uridine 5'-diphospho-glucuronosyltransferase enzymes by the other agents),
* cardiac MRI-incompatible cardiac devices (cardiac pacemaker, implanted cardiac defibrillator, internal pacing wires, Swan-Ganz catheter, aneurysm clips),
* claustrophobia,
* cochlear implants,
* metallic body in the eyes,
* pregnancy or breastfeeding,
* and any other medical condition considered to be a contra-indication by the study physician.

Where it's running

• McGill University Health Center
  Montreal, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Thomas Mavrakanas, MD — McGill University Health Centre/Research Institute of the McGill University Health Centre
• Study coordinator: Efrosyne Tsirella, Research Assistant
• Email: efrosyne.tsirella@muhc.mcgill.ca
• Phone: 514-934-1934

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Omnisol-preserved kidneys before transplant (hypothermic machine perfusion)

  This study tests whether using Omnisol during hypothermic machine perfusion before kidney transplant can improve early graft function compared with standard preservation.

  Recruiting Vivalyx GmbH · Rotterdam · NCT07792317

• Remote monitoring in dialysis: comparing RPM-APD, manual PD, and maintenance HD

  This study tests how well three dialysis approaches work for adults with ESRD starting dialysis in China, using real-world data from routine care.

  Recruiting Vantive Health LLC · Beijing, Beijing Municipality and 19 other locations · NCT07781124

• Extra Ultrafiltration to Remove Fluid in Hemodialysis Patients

  This trial tests whether adding extra ultrafiltration over 4 or 8 weeks helps people on in-center hemodialysis reduce excess body fluid and lower blood pressure.

  Recruiting University of Washington · Seattle, Washington · NCT07637110

• Calciphylaxis in people with chronic kidney disease: causes, risks, and early signs

  This project will compare adults with chronic kidney disease who develop calciphylaxis to matched CKD patients who do not, collecting clinical data and biological samples to try to find risk factors and early signs.

  Recruiting Odense University Hospital · Odense · NCT07511283

• Comparing physical therapy during dialysis versus before dialysis for adults on hemodialysis

  This project tests whether supervised exercises done during dialysis or before dialysis help adults on hemodialysis improve physical function, quality of life, and blood measures like hemoglobin and electrolytes.

  Recruiting Ministry of Health, Kuwait · Hawalli · NCT07361146

• WeChat 'Yueya' app support for people on maintenance hemodialysis

  This project will test whether the 'Yueya' mini-program on WeChat helps people on maintenance hemodialysis follow treatment, feel better, and have fewer complications.

  Recruiting First Affiliated Hospital of Chongqing Medical University · Chongqing, Chongqing Municipality · NCT07291154

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.